Recent News and Announcements
Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation
- Transaction values Avertix at an enterprise value of $195 million- Avertix developed the Guardian™ System, the first and only FDA-approved solution designed to detect and warn patients of cardiac events, including silent heart attacks EATONTOWN,...
8-K Filing Pursuant to Full Exercise of Over-Allotment Option
BioPlus Acquisition Corp. Announces Pricing of Upsized $200,000,000 Initial Public Offering
New York, NY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (the “Company”) announced today that it priced its upsized initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global...
"We are focused on the life sciences industry across the US, EU, Israel and Australasia(1), where we have deep clinical, regulatory, operational and commercial expertise. Furthermore, we believe our management team and board’s extensive experience positions us to be therapeutic area agnostic. We plan to identify and assess target assets leading to an efficient pathway to a merger."
Ross Haghighat, CEO & CFO
(1) Excluding China, Hong Kong and Macau
“SPACs with operators at the helm outperformed others”
“Operator-led SPACs are more focused and better governed”